A New Drug Candidate TB511 Shows Promise for Hard-to-Treat Prostate Cancer

Castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, APMR) is one of the toughest forms of prostate cancer to treat. It becomes resistant to hormone therapy, and current immunotherapies don’t work well on it. The main reason is that CRPC tumors create an immune-“cold” environment filled with M2 macrophages, a type of immune cell that actually helps the tumor grow instead of fighting it. A new study published on Nature shows that a drug called TB511 can selectively kill these bad M2 macrophages and reprogram the tumor environment to fight back.

TB511 is a peptide-drug conjugate, which means it’s made of three parts working together. First, it has a targeting peptide (called TAMpep) that seeks out CD18, a protein found mostly on M2 macrophages in tumors. Second, it uses a flexible linker to connect the parts. Third, it carries a pro-apoptotic peptide (D-KLA) that kills cells by damaging their mitochondria, the cell’s power plants. The drug binds very tightly to CD18, only targets M2 macrophages and not healthy M1 macrophages, and goes straight to mitochondria where it triggers cell death.

In lab experiments, TB511 worked exactly as designed. It killed M2 macrophages effectively while leaving M1 macrophages and tumor cells alone. When researchers grew tumor spheroids (3D clusters of cancer cells) together with macrophages, adding TB511 slowed tumor growth. The drug also reduced markers for cell division (Ki-67) and metastasis (vimentin), suggesting it helps stop cancer from spreading. Importantly, TB511 didn’t kill tumor cells directly. It worked by removing the M2 macrophages that were protecting and feeding the tumor.

The drug was then tested in mouse models, including a humanized model where mice had human immune cells and human prostate cancer cells (PC-3) implanted. In both regular mouse models and humanized models, TB511 significantly reduced tumor size and weight. Live imaging confirmed that TB511 accumulated specifically in tumors and landed on M2 macrophages (marked by CD206 and CD18). This proved the drug reaches its target in living organisms, not just in a dish.

The most exciting finding was how TB511 changed the entire tumor environment. After treatment, there were fewer M2 macrophages and more M1 macrophages, flipping the balance from tumor-supporting to tumor-fighting. T cells (CD8+ T cells) that were previously exhausted became activated again. Natural killer (NK) cells also became more active. The drug reduced markers for metastasis (EMT), blood vessel formation (angiogenesis), and cell division. In other words, removing just one type of cell (M2 macrophages) triggered a chain reaction that made the whole immune system work better against the tumor.

The mechanism is straightforward. TB511 binds to CD18 on M2 macrophages with very high affinity. The drug’s KLA part damages mitochondria and kills the M2 macrophages. With the suppressive M2 cells gone, T cells and NK cells can start working again. New M1 macrophages move in and create a pro-inflammatory environment. Tumor cells infiltrated by active immune cells get killed. The altered environment also reduces metastasis, blood vessel growth, and tumor cell division. This proves that M2 macrophages are key drivers of immune suppression in CRPC.

This matters for patients because CRPC currently has few treatment options. TB511 could be combined with checkpoint inhibitors (like PD-1 blockades) that currently don’t work well in cold tumors, since TB511 would first make the tumor environment hot and immune-active. Compared to other macrophage-targeting approaches, TB511 is more precise (only kills M2, not M1), penetrates tumors better (small peptide vs. large antibodies), and depletes existing M2 cells instead of just blocking new ones from arriving.

This 2026 prostate cancer study builds on earlier 2025 work showing TB511 works in colorectal cancer, lung cancer, and pancreatic cancer. The fact that it works across different tumor types suggests it could be a broad immunotherapy platform, not just for prostate cancer.

Source.